Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 10/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12871218 | 1.00 | CYP19A1 (0.45) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL12871217 | 1.00 | CYP19A1 (0.45) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL8236808 | 1.00 | CYP19A1 (0.45) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL12313924 | 1.00 | CYP19A1 (0.45) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL1180028 | 0.80 | CYP19A1 (0.49) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL5133449 | 0.75 | CYP19A1 (0.48) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL5571001 | 0.75 | CYP19A1 (0.48) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL5048062 | 0.75 | CYP19A1 (0.48) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL1180397 | 0.73 | CYP19A1 (0.42) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL2916227 | 0.72 | CYP19A1 (0.44) | CYP19A1CYP11B2CYP11B1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263615-B2 | Bis-heterocyclic imidazolyl compounds | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-20110028512-A1 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | HEROLD PETER | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028512-A1 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | CYP11B1, CYP11B2, REN | CYP19A1 43/4885CYP11B2 2/4885CYP11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.